• Stefan H E Kaufmann, Gregory Hussey, and Paul-Henri Lambert.
• Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany. kaufmann@mpiib-berlin.mpg.de
• Lancet. 2010 Jun 12;375(9731):2110-9.

AbstractNew vaccines are urgently needed if we want to reach the goal of substantially reducing the incidence of tuberculosis by 2050. Despite a steady increase in funding over the past decade, there is still a striking financial shortfall for vaccine research and development for tuberculosis. Yet, around ten vaccine candidates have left the laboratory stage and entered clinical trials. These vaccines are either aimed at replacing the present vaccine, BCG, or at enhancing immunity induced by BCG. However, these pre-exposure candidates are designed for prevention of disease and will therefore neither eradicate the pathogen, nor prevent stable infection. Long-term vaccination strategies need to target these more ambitious goals. Even though vaccine development will have a price, the return of investment will greatly exceed original costs.Copyright 2010 Elsevier Ltd. All rights reserved.

8 keywords...

hide…